<DOC>
	<DOCNO>NCT02270099</DOCNO>
	<brief_summary>This clinical performance study conduct evaluate performance Aptima Herpes Simplex Viruses 1 &amp; 2 assay detection herpes simplex virus ( HSV ) type 1 ( HSV-1 ) HSV type 2 ( HSV-2 ) swab sample prospectively collect suspected HSV lesion male anogenital region , female anogenital region , oral cavity mucomembranous mucocutaneous area face ( oral/facial ) , skin . Specimens collect use swabs viral transport medium ( VTM ) collection kit Aptima swab collection kit evaluate .</brief_summary>
	<brief_title>Evaluation HSV 1 &amp; 2 Assay Specimens From Symptomatic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Herpes Simplex</mesh_term>
	<criteria>The subject least 1 active lesion ( lesion exudate cellular material ; eg , vesicle , ulcer ) suspect cause HSV ( determined clinician ) The subject and/or legally authorize representative willing able provide consent prior study participation ( minor need document consent his/her parent legal guardian , unless site institutional review boardapproved waiver parental consent minor ) The subject HSV lesion without exudate cellular material The subject use topical oral antiviral medication use treat HSV within 21 day enrollment Subject already participate study Subject history illness principal investigator ( PI ) designee considers could interfere affect conduct , result , and/or completion study Subject history illness PI designee considers could create unacceptable risk subject enrol study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>